The Bill & Melina Gates Foundation had already invested $52 million in CureVac, back in 2015, and has now doubled down on its investment, as the biotech announced that the foundation had boosted its funding by giving two more grants.
Details on the scale and exact use of the grants were limited in the press release, with CureVac only revealing that the money will be harnessed to utilise its RNActive prophylactic vaccine technology to develop mRNA-based vaccines. The two targets of the vaccines will be the influenza and malaria viruses.
Image caption:
IMAGE: Wikipedia/Abdar
